Sanofi and Teva had already shown in late 2024 that the anti-TL1A antibody, called duvakitug, improved outcomes in ulcerative ...

Teva Pharmaceutical Industries Limited TEVA shares are higher during Tuesday’s premarket session as the company is discussing ...

NImmune Biopharma ("NImmune"), a private late-stage precision inflammation and immunology ("I&I") biopharmaceutical company, today announced that Executive Chairman, President and CEO Dr. Josep ...

A new study suggests that combining routine stool tests and tracking habitual dietary patterns could help to predict IBD ...

"Our results indicate that [the presence of micro- and nanoplastics] is a previously underestimated factor in the development ...

Precancerous colorectal lesions, or dysplasia, in patients with inflammatory bowel disease (IBD) confer markedly different risks of future colorectal cancer depending on dysplasia grade, according to ...

A recent study revealed that intermittent fasting may assist patients accomplish long-term remission from Crohn’s ...

Patients with inflammatory bowel disease and precancerous colorectal lesions face an increased risk of developing colorectal cancer, with risk levels tied to the severity of the lesions, according to ...

Inflammatory bowel disease (IBD) is an umbrella term for a group of chronic conditions that cause inflammation and swelling ...

Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 ...

Inflammatory bowel disease (IBD) is typically diagnosed after the onset of symptoms in the context of established, characteristic patterns of intestinal inflammation. However, there is now substantial ...